How Payers Can Save an Average of $25,579 Per Patient by Eliminating Unwarranted, Non-Evidence-Based Cancer Treatment

Evidence-based care leads to better clinical outcomes, but how does it affect your cost?

A multi-year study performed in association with professionals from Abramson Cancer Center of the University of Pennsylvania and Johns Hopkins Carey Business School revealed that the cost of unwarranted components of oncology treatments averaged $25,579 per patient.

At current annual cancer incidence rates in the US, this translates to over $10 billion per year in unnecessary costs that could be significantly reduced by eliminating unwarranted, non-evidence-based cancer treatment.

To find out how to download this white paper on HealthPayerIntelligence, click here.